What is Anavex Life Sciences Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Anavex Life Sciences's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.96 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Anavex Life Sciences's Operating Income for the
three
months ended in Dec. 2023 was $ -11.29 Mil. Anavex Life Sciences's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Anavex Life Sciences has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Anavex Life Sciences Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (NAS:AVXL) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Anavex Life Sciences's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-11.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $0.00 Mil.
Anavex Life Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| Anavex Life Sciences had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Anavex Life Sciences (Anavex Life Sciences) Business Description
Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Executives
| Christopher U Missling |
director, officer: President, CEO, CFO, Treasurer, other: Secretary |
61 MOULTON ST, CAMBRIDGE MA 02138 |
| Athanasios Skarpelos |
10 percent owner |
14,RUE KLEBERG, GENEVA V8 CH-1201 |
| Jiong Ma |
director |
445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022 |
| Elliot Favus |
director |
51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091 |
| Donhauser Peter D.o. |
director |
REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600 |
| Sandra Boenisch |
officer: PFO & Treasurer |
51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019 |
| Claus Vander Velden |
director |
PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937 |
| Steffen Thomas |
director |
FALLMERAYER STR. 19, MUNICH 2M 80796 |
| Bernd Metzner |
director |
51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019 |
| George F Tidmarsh |
director, officer: Executive Director |
|
| John Robert Chisholm |
director |
16308 36A AVENUE, SURREY A1 V3S 0X5 |
| William Sean Lowry |
director |
1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9 |
| David L. Tousley |
director |
14610 PAWNEE LANE, LEAWOOD KS 66224 |
| Harvey Lalach |
director, officer: President CEO CFO |
4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1 |
| Alison E. Ayers |
director |
27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052 |
Anavex Life Sciences (Anavex Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your 